Cochrane · systematic review · CD015308
Interleukin‐1 blocking agents for treating COVID‐19
Davidson, M, Menon, S, Chaimani, A, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Emergency and Critical CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
20
No studies
2
Included studies
NR
No studies 2 · 9.1%Ungraded 0 · 0%Very low 3 · 13.6%Low 12 · 54.5%Moderate 5 · 22.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anakinra compared to standard care/placebo for mild/moderate/severe/critical COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical improvement D28 Anakinra vs standard care/placebo | RR 1.08 [0.97, 1.2] | 3 studies · 837 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Clinical improvement D60 or above Anakinra vs standard care/placebo | RR 0.93 [0.78, 1.12] | 1 study · 115 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
WHO Clinical Progression Score of level 7 or above D28 Anakinra vs standard care/placebo | RR 0.67 [0.36, 1.22] | 2 studies · 722 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
WHO Clinical Progression Score of level 7 or above D60 or above Anakinra vs standard care/placebo | RR 0.54 [0.3, 0.96] | 1 study · 606 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
All‐cause mortality D28 Anakinra vs standard care/placebo | RR 0.69 [0.34, 1.39] | 2 studies · 722 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
All‐cause mortality D60 or above Anakinra vs standard care/placebo | RR 1.03 [0.68, 1.56] | 4 studies · 1633 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events Anakinra vs standard care/placebo | RR 1.02 [0.94, 1.11] | 2 studies · 722 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events Anakinra vs standard care/placebo | RR 0.95 [0.58, 1.56] | 2 studies · 722 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Time to clinical improvement Anakinra vs standard care/placebo | HR 1.07 [0.91, 1.26] | 4 studies · 1633 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Time to WHO Clinical Progression Score of level 7 or above Anakinra vs standard care/placebo | HR 0.69 [0.48, 0.99] | 2 studies · 722 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Time to death Anakinra vs standard care/placebo | HR 0.8 [0.59, 1.08] | 3 studies · 1518 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Canakinumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical improvement D28 Canakinumab vs standard care/placebo | RR 1.05 [0.96, 1.14] | 2 studies · 499 participants | Moderate Downgraded: imprecision, indirectness |
Clinical improvement D60 or above Canakinumab vs standard care/placebo | no estimate extracted | NR | No studies |
WHO Clinical Progression Score of level 7 or above D28 Canakinumab vs standard care/placebo | RR 0.72 [0.44, 1.2] | 2 studies · 499 participants | Low Downgraded: imprecision, indirectness |
WHO Clinical Progression Score of level 7 or above D60 or above Canakinumab vs standard care/placebo | no estimate extracted | NR | No studies |
All‐cause mortality D28 Canakinumab vs standard care/placebo | RR 0.75 [0.39, 1.42] | 2 studies · 499 participants | Low Downgraded: imprecision, indirectness |
All‐cause mortality D60 or above Canakinumab vs standard care/placebo | RR 0.55 [0.16, 1.91] | 1 study · 45 participants | Very low Downgraded: imprecision, indirectness |
Adverse events Canakinumab vs standard care/placebo | RR 1.02 [0.86, 1.21] | 1 study · 454 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events Canakinumab vs standard care/placebo | RR 0.8 [0.57, 1.13] | 2 studies · 499 participants | Low Downgraded: imprecision, indirectness |
Time to clinical improvement Canakinumab vs standard care/placebo | HR 1.06 [0.87, 1.29] | 1 study · 454 participants | Moderate Downgraded: imprecision, indirectness |
Time to WHO Clinical Progression Score of level 7 or above Canakinumab vs standard care/placebo | HR 0.8 [0.47, 1.36] | 1 study · 454 participants | Low Downgraded: imprecision, indirectness |
Time to death Canakinumab vs standard care/placebo | HR 0.71 [0.36, 1.43] | 2 studies · 499 participants | Low Downgraded: imprecision, indirectness |